title: Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand.
abstract: Trastuzumab (TZ) is a humanized monoclonal antibody targeted to the extracellular domain of human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor. TZ is approved by the Food and Drug Administration (FDA) for the treatment of HER2-overexpressing early stage and metastatic breast cancer and HER2-overexpressing metastatic gastric cancer. For breast cancer, it is recommended as both a single agent and in combination with standard chemotherapy. In the last few years, TZ has also been used as a targeting ligand. Overexpression of HER2 in breast cancer and the presence of free surface functional groups on TZ provide an opportunity to use it as a targeting ligand. TZ can be conjugated to various nanoparticulate systems such as dendrimers, polymeric, and protein nanoparticles to target drug delivery. TZ-conjugated inorganic nanoparticles have been reported for imaging and diagnostic purposes. This review summarizes the applications of TZ both as a therapeutic agent and as a targeting ligand.
authors.affiliation: IICT-RMIT Research Centre, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.|Medicinal Chemistry & Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.|Health Innovations Research Institute, RMIT University, Melbourne, VIC, 3083, Australia.
authors.forename: Hitesh
authors.initials: H
authors.lastname: Kulhari
authors.affiliation: Medicinal Chemistry & Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.
authors.forename: Deep
authors.initials: D
authors.lastname: Pooja
authors.affiliation: Medicinal Chemistry & Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.
authors.forename: Sri V K
authors.initials: SV
authors.lastname: Rompicharla
authors.affiliation: Medicinal Chemistry & Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.
authors.forename: Ramakrishna
authors.initials: R
authors.lastname: Sistla
authors.affiliation: Health Innovations Research Institute, RMIT University, Melbourne, VIC, 3083, Australia.
authors.forename: David J
authors.initials: DJ
authors.lastname: Adams
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D035843:Biomedical Research; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008024:Ligands; D000068878:Trastuzumab / Q000627:therapeutic use*
chemical_list: D014408:Biomarkers, Tumor; D008024:Ligands; D000068878:Trastuzumab
keywords: T-DM1; breast cancer; chemotherapy; ligand; trastuzumab